European Directive on Traditional Herbal Medicinal Products

Last updated

Directive 2004/24/EC
European Union directive
Flag of Europe.svg
TitleDirective on Traditional Herbal Medicinal Products
Made by European Parliament & Council
Made underArticle 95
Journal reference L136, 30 April 2004, pp. 85–90
History
Date made31 March 2004
Came into force30 April 2004
Implementation date30 October 2005
Other legislation
Amends Directive 2001/83/EC
Current legislation

The European Directive on Traditional Herbal Medicinal Products (THMPD), formally the Directive 2004/24/EC amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use, was established by the European Parliament and Council on 31 March 2004 to provide a simplified regulatory approval process for traditional herbal medicines in the European Union (EU). [1] [2] Previously, there was no formal EU wide authorisation procedure, so each EU member state regulated these types of products at the national level. [3]

Under this regulation, all herbal medicinal products are required to obtain an authorisation to market within the EU. Those products marketed before this legislation came into force can continue to market their product until 30 April 2011, under the transitional measures defined in the Traditional Herbal Medicinal Products Directive. Once this time limit has expired, all herbal medicinal products must have prior authorisation before they can be marketed in the EU. [1]

For those herbal medicinal products that were not on the market before 30 April 2004, an authorisation must be obtained prior to marketing. [1]

The only herbal medicines that are exempted from the provisions of the Traditional Herbal Medicinal Products Directive are those unlicensed remedies that are made up for a patient following a consultation with a herbalist. [4]

Herbal medicines must be now manufactured under Good Manufacturing Practice (GMP) to ensure the quality of the finished product and also demonstrate safety. [5]

Under the Traditional Herbal Medicinal Products Directive, a company needs to demonstrate that the herbal medicine has been in use within the EU for at least 30 years or 15 years within the EU and 30 years outside the EU. [5] There is concern that some herbal remedies of 30 years ago, which are no longer in widespread use, could still be sold but that valid new herbs which cannot meet the 30-year rule may require to be withdrawn from sale. The rule could also mean that it may not be possible to license some traditional herbal medicines which were in common use more than 30 years ago, but have since fallen into disuse.

There are key eligibility criteria for a herbal medicine to qualify under this legislation: [6]

The Traditional Herbal Medicines Product Directive does allow medicinal claims to be made on the label of the final product, although restrictions do apply on the final wording. [7]

Related Research Articles

<span class="mw-page-title-main">Regulation of therapeutic goods</span> Legal management of drugs and restricted substances

The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level, or at both state and national levels by various bodies, as in Australia.

Pharmacovigilance, also known as drug safety, is the pharmaceutical science relating to the "collection, detection, assessment, monitoring, and prevention" of adverse effects with pharmaceutical products. The etymological roots for the word "pharmacovigilance" are: pharmakon and vigilare. As such, pharmacovigilance heavily focuses on adverse drug reactions (ADR), which are defined as any response to a drug which is noxious and unintended, including lack of efficacy. Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.

<span class="mw-page-title-main">European Medicines Agency</span> Agency of the European Union

The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency (EMEA).

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department of Health and Social Care in the United Kingdom which is responsible for ensuring that medicines and medical devices work and are acceptably safe.

A novel food is a type of food that does not have a significant history of consumption or is produced by a method that has not previously been used for food.

<span class="mw-page-title-main">Supplementary protection certificate</span> Type of intellectual property right

In the European Economic Area, a supplementary protection certificate (SPC) is a sui generis intellectual property (IP) right that extends the duration of certain rights associated with a patent. It enters into force after expiry of a patent upon which it is based. This type of right is available for various regulated, biologically active agents, namely human or veterinary medicaments and plant protection products. Supplementary protection certificates were introduced to encourage innovation by compensating for the long time needed to obtain regulatory approval of these products.

<span class="mw-page-title-main">Health food store</span>

A health food store is a type of grocery store that primarily sells health foods, organic foods, local produce, and often nutritional supplements. Health food stores typically offer a wider or more specialized selection of foods than conventional grocery stores for their customers, for example people with special dietary needs, such as people who are allergic to the gluten in wheat or some other substance, and for people who observe vegetarian, vegan, raw food, organic, or other alternative diets.

<i>European Pharmacopoeia</i> Major multinational pharmacopoeia published by the European Union

The European Pharmacopoeia is a major regional pharmacopoeia which provides common quality standards throughout the pharmaceutical industry in Europe to control the quality of medicines, and the substances used to manufacture them. It is a published collection of monographs which describe both the individual and general quality standards for ingredients, dosage forms, and methods of analysis for medicines. These standards apply to medicines for both human and veterinary use.

The Yellow Card Scheme is the United Kingdom's system for collecting information on suspected adverse drug reactions (ADRs) to medicines. The scheme allows the safety of the medicines and vaccines that are on the market to be monitored.

<span class="mw-page-title-main">EudraLex</span> EU laws on medicinal products

EudraLex is the collection of rules and regulations governing medicinal products in the European Union.

The Clinical Trials Directive is a European Union directive that aimed at facilitating the internal market in medicinal products within the European Union, while at the same time maintaining an appropriate level of protection for public health. It seeks to simplify and harmonise the administrative provisions governing clinical trials in the European Community, by establishing a clear, transparent procedure.

<span class="mw-page-title-main">European Directorate for the Quality of Medicines & HealthCare</span> International organisation

The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a Directorate of the Council of Europe that traces its origins and statutes to the Convention on the Elaboration of a European Pharmacopoeia.

The Alliance for Natural Health (ANH) is an advocacy group founded in 2002 by Robert Verkerk and based in the United Kingdom. ANH was founded to raise funds to finance a legal challenge of the EU Food Supplement Directive. ANH lobbies against regulation of dietary supplements, in favour of pseudo-scientific alternative medicine, and advocates dietary and other lifestyle approaches to health. It also criticizes established science showing that Megavitamin therapy lack any health benefit.

Marketing Authorisation Application (MAA) is an application submitted by a drug manufacturer seeking marketing authorisation, that is permission to bring a medicinal product to the market.

Marketing authorisation is the process of reviewing and assessing the evidence to support a medicinal product, such as a drug, in relation to its marketing, finalised by granting of a licence to be sold.

Because of the uncertain nature of various alternative therapies and the wide variety of claims different practitioners make, alternative medicine has been a source of vigorous debate, even over the definition of "alternative medicine". Dietary supplements, their ingredients, safety, and claims, are a continual source of controversy. In some cases, political issues, mainstream medicine and alternative medicine all collide, such as in cases where synthetic drugs are legal but the herbal sources of the same active chemical are banned.

<span class="mw-page-title-main">Human Medicines Regulations 2012</span> United Kingdom legislation

The Human Medicines Regulations 2012 in the United Kingdom were created, under statutory authority of the European Communities Act 1972 and the Medicines Act 1968 in 2012. The body responsible for their upkeep is the Medicines and Healthcare products Regulatory Agency. The regulations partially repealed the Medicines Act 1968 in line with EU legislation.

<span class="mw-page-title-main">Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020</span> Amendment Regulations for Human Medicines (Coronavirus and Influenza) in England

The Human Medicines (Amendment) Regulations 2020 is a statutory instrument (SI) that was laid before Parliament on 16 October 2020 to make provision for the strengthening of existing regulations that allow for the temporary authorisation of the supply of unlicensed medicines, including vaccines, in response to certain public health threats, and for the expansion of the workforce able to administer the COVID-19 vaccines and influenza vaccines. Certain amendments within the instrument, regulations 3, 12 and 3, allowing for the administration of vaccines by a wider range of medically trained people such as an "occupational health vaccinator" are time-limited to 1 April 2022.

<span class="mw-page-title-main">Valneva COVID-19 vaccine</span> Vaccine candidate against COVID-19

Valneva COVID-19 vaccine is a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies.

References

  1. 1 2 3 "EUR-Lex – 32004L0024 – EN – EUR-Lex". eur-lex.europa.eu.
  2. "EUR-Lex – 32001L0083 – EN – EUR-Lex". eur-lex.europa.eu.
  3. "Unlicensed herbal remedies: over-the-counter products splashpage". Medicines and Healthcare products Regulatory Agency. Archived from the original on 5 December 2014. Retrieved 8 June 2016.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  4. "Error page". Medicines and Healthcare products Regulatory Agency. Archived from the original on 5 December 2014. Retrieved 8 June 2016.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  5. 1 2 "Traditional Herbal Medicines Registration Scheme: Key requirements – in more detail". Medicines and Healthcare products Regulatory Agency. Archived from the original on 5 December 2014. Retrieved 8 June 2016.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  6. "Traditional Herbal Medicines Registration Scheme: Scope – what products are covered". Medicines and Healthcare products Regulatory Agency (MHRA), www.mhra.gov.uk. Government of the United Kingdom. Archived from the original on 5 December 2014. Retrieved 8 June 2016.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  7. "Error page". Medicines and Healthcare products Regulatory Agency. Archived from the original on 5 December 2014. Retrieved 8 June 2016.{{cite web}}: CS1 maint: bot: original URL status unknown (link)